Market Herald logo

Subscribe

Be the first with the news that moves the market
  • ProMIS Neurosciences (PMN) will participate in the 2020 BIO CEO & Investor Conference in New York.
  • The company’s Executive Chairman, Eugene Williams, will give a presentation during the conference.
  • Mr Williams will present data which supports the company’s antibody program for neurodegenerative diseases.
  • ProMIS’s share price remains unchanged, with shares trading at $0.22 apiece.

Biotechnology company ProMIS Neurosciences (PMN) will send a representative to attend and participate in the 2020 BIO CEO & Investor Conference.

The 2-day long conference will be hosted at the Marriott Marquis Hotel in New York City.

The event will bring together investors, industry analysts, and senior executives from biotechnology and pharmaceutical companies like ProMIS.

The conference will take place on February 10th and 11th, with company presentations on both days.

The Executive Chairman of ProMIS, Eugene Williams, will give a presentation at 3:00pm (Eastern Time) on February 11th.

In his presentation, Mr Williams will present data that supports ProMIS’ antibody programs for targeting and treating neurodegenerative diseases, such as Alzheimer’s, Parkinson’s, and ALS.

Unfortunately, webcasting will not be available for the event.

ProMIS’s share price remains unchanged, with shares trading at $0.22 apiece.

More From The Market Herald
Featured Video Play Icon

" OpSens (TSX:OPS) announces first SavvyWire procedure in the U.S.

OpSens (OPS) is announcing the first SavvyWire procedure in the U.S.

" Lobe Sciences (CSE:LOBE) incorporates Australian subsidiary for psilocin trials

Lobe Sciences (LOBE) has incorporated its wholly-owned Australian subsidiary to facilitate three or more clinical trials.
Featured Video Play Icon

" Rapid Dose Therapeutics (CSE:DOSE) to supply leading gas and convenience store retailer

Rapid Dose (DOSE) has signed a supplier agreement with a leading gas and convenience store retailer.

" NervGen Pharma (TSXV:NGEN) announces leadership changes

NervGen Pharma Corp. (NGEN) has announced several leadership changes.